title: Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target.
abstract: Leukemia cells are protected by various components of their microenvironment, including marrow stromal cells (MSCs). To understand the molecular mechanisms underlying this protection, we cultured acute lymphoblastic leukemia (ALL) cells with MSCs and studied the effect of the latter on the molecular profiling of ALL cells at the mRNA and protein levels. Our results indicated that activated Wnt signaling in ALL cells is involved in MSC-mediated drug resistance. Blocking the Wnt pathway sensitized the leukemia cells to chemotherapy and improved overall survival in a mouse model. Targeting the Wnt pathway may be an innovative approach to the treatment of ALL.
authors: Department of Bone Marrow Transplant Center, First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou, Zhejiang, China.
authors: Yang
authors: Y
authors: Yang
authors: Saradhi
authors: S
authors: Mallampati
authors: Baohua
authors: B
authors: Sun
authors: Jing
authors: J
authors: Zhang
authors: Sang-Bae
authors: SB
authors: Kim
authors: Ju-Seog
authors: JS
authors: Lee
authors: Yun
authors: Y
authors: Gong
authors: Zhen
authors: Z
authors: Cai
authors: Xiaoping
authors: X
authors: Sun
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle; D003561:Cytarabine / Q000494:pharmacology; D015973:Gene Expression Regulation, Leukemic; D006575:Heterocyclic Compounds, 3-Ring / Q000494:pharmacology; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D051379:Mice; D016513:Mice, SCID; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D060449:Wnt Signaling Pathway / Q000502:physiology*; D051176:beta Catenin / Q000502:physiology
chemical_list: C495270:CTNNB1 protein, human; D006575:Heterocyclic Compounds, 3-Ring; C544261:XAV939; D051176:beta Catenin; D003561:Cytarabine